Ronnie T.P. Poon;Wai Kuen Tso;Roberta W.C. Pang;Kelvin K.C. Ng;Regina Woo;Kin Shing Tai;上达 范
The University of Hong Kong;China Association for Science and Technology
发表时间:2007-9
期 刊:Clinical Gastroenterology and Hepatology
语 言:English
U R L: http://www.scopus.com/inward/record.url?scp=35748960546&partnerID=8YFLogxK
Background & Aims: To assess the safety and efficacy of transarterial chemoembolization (TACE) using doxorubicin-eluting beads (DEB) for hepatocellular carcinoma (HCC). Methods: Patients with incurable HCC and Child-Pugh class A cirrhosis were considered eligible for this phase I/II trial. Two courses of TACE using DEB were given at an interval of 2 months, and tumor response was assessed by computerized tomography scan. The phase I trial was a dose-escalating study starting from 25 mg to 150 mg doxorubicin in cohorts of 3 patients. The 150-mg doxorubicin dose was used for the phase II study. Primary end points were treatment-related complications and deaths. Secondary end points included tumor response and pharmacokinetics of doxorubicin. Results: In the phase I study involving 15 patients, no dose-limiting toxicity was observed for up to 150 mg doxorubicin, which was used for 20 patients in the phase II study. The pharmacokinetic study showed a low peak plasma doxorubicin concentration (49.4 ± 23.7 ng/ mL), and no systemic toxicity was observed. The treatmentrelated complication rate was 11.4%. There was no treatmentrelated death. Among 30 patients who completed 2 courses of TACE, the partial response rate and the complete response rates were 50% and 0%, respectively, by response evaluation criteria in solid tumors (RECIST) criteria at computerized tomography scan 1 month after the second TACE. By modified RECIST criteria, taking into account the extent of tumor necrosis, 19 (63.3%) patients had a partial response and 2 (6.7%) had a complete response. Conclusions: This study shows that TACE using DEB is a safe and effective treatment for HCC, supporting a phase III randomized trial to compare this novel treatment with conventional TACE using doxorubicin-Lipiodol emulsion.
医学与生命科学
Scopus度量
年份 | CiteScore | SJR | SNIP |
---|---|---|---|
1996 | |||
1997 | |||
1998 | |||
1999 | |||
2000 | |||
2001 | 0.12 | ||
2002 | 0.217 | 0 | |
2003 | 0.17 | 0.086 | |
2004 | 0.648 | 1.063 | |
2005 | 1.53 | 1.744 | |
2006 | 2.095 | 1.471 | |
2007 | 2.218 | 1.715 | |
2008 | 2.252 | 1.617 | |
2009 | 2.153 | 1.675 | |
2010 | 2.003 | 1.592 | |
2011 | 7.6 | 1.906 | 1.523 |
2012 | 7.4 | 1.966 | 1.436 |
2013 | 7.8 | 2.431 | 1.616 |
2014 | 9 | 2.859 | 1.836 |
2015 | 10 | 2.947 | 1.793 |
2016 | 11.1 | 3.139 | 1.77 |
2017 | 11.1 | 3.23 | 1.684 |
2018 | 10.9 | 2.72 | 1.791 |
2019 | 9.5 | 2.223 | 1.752 |
2020 | 9.3 |
相似文献推荐